Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tablet replace the Doctor's office for memory tests?

NCT ID NCT07664865

Diagnosis Sponsor: IRCCS National Neurological Institute "C. Mondino" Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a tablet-based platform called Tenèpsia® for remote cognitive assessments in 250 healthy adults and people with cognitive impairment. The goal was to collect normal test scores and validate the digital tool for diagnosing neurocognitive disorders. If proven reliable, it could make cognitive testing more accessible, especially for those who have trouble traveling to clinics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tenèpsia® tablet-based teleneuropsychological platform
What this could lead to
If successful, this could provide a reliable, remote way to assess cognitive decline, making diagnosis more accessible for older adults with mobility issues or in rural areas.
What could go wrong
This is a validation study, not a treatment trial. It focuses on standardizing the digital test, not on improving health outcomes. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

250 people

The number who actually took part.

Started

Dec 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

200 healthy subjects and 50 patients with a diagnosis of Mild Neurocognitive Disorder (mNCD), equally distributed between the collaborating centers

Ages

40 to 89 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Criteria of Healthy subjects: * Inclusion: age between 40 and 89 years; Montreal Cognitive Assessment (MoCA) adjusted score greater than or equal to 23; * Exclusion: sensory deficits (e.g., hypovision, hearing loss) and/or reported chronic pain potentially affecting teleneuropsychological performance; chronic treatment with psychotropic drugs and/or potentially interfering with cognitive functions in the opinion of the recruiting physician. Criteria of Pathological subjects: * Inclusion: age between 40 and 89 years; diagnosis of mNCD according to the DMS-5; * Exclusion: pathological subjects: sensory deficits (e.g., hypovision, hearing loss) and/or reported chronic pain potentially affecting teleneuropsychological performance; chronic treatment with psychotropic drugs and/or potentially interfering with cognitive functions in the opinion of the recruiting physician; history of cerebrovascular disease, head trauma, or brain tumor; alcoholism; severe internal medicine pathologies associated with cognitive deficit (e.g., organ failure, endocrine pathologies, particularly thyroid and B12/folate deficiency).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive impairment

Contacts and locations

Locations

  • Unit of Research in Cognitive Psychology

    Pavia, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.